BLACK DIAMOND THERAPEUTICS I (BDTX) Fundamental Analysis & Valuation

NASDAQ:BDTX • US09203E1055

Current stock price

2.17 USD
-0.06 (-2.69%)
At close:
2.18 USD
+0.01 (+0.46%)
After Hours:

This BDTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BDTX Profitability Analysis

1.1 Basic Checks

  • BDTX had positive earnings in the past year.
  • In the past year BDTX had a positive cash flow from operations.
  • In the past 5 years BDTX always reported negative net income.
  • In the past 5 years BDTX always reported negative operating cash flow.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • BDTX's Return On Assets of 13.62% is amongst the best of the industry. BDTX outperforms 94.59% of its industry peers.
  • BDTX has a better Return On Equity (17.03%) than 94.98% of its industry peers.
  • The Return On Invested Capital of BDTX (6.74%) is better than 92.28% of its industry peers.
Industry RankSector Rank
ROA 13.62%
ROE 17.03%
ROIC 6.74%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 30.69%, BDTX belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
  • The Operating Margin of BDTX (17.33%) is better than 93.44% of its industry peers.
Industry RankSector Rank
OM 17.33%
PM (TTM) 30.69%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BDTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BDTX has more shares outstanding
  • The number of shares outstanding for BDTX has been increased compared to 5 years ago.
  • BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of 0.06, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.06, BDTX is in line with its industry, outperforming 59.65% of the companies in the same industry.
  • BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.06
ROIC/WACCN/A
WACCN/A
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • BDTX has a Current Ratio of 8.94. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
  • BDTX has a Current ratio of 8.94. This is in the better half of the industry: BDTX outperforms 76.64% of its industry peers.
  • BDTX has a Quick Ratio of 8.94. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
  • BDTX has a better Quick ratio (8.94) than 76.64% of its industry peers.
Industry RankSector Rank
Current Ratio 8.94
Quick Ratio 8.94
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. BDTX Growth Analysis

3.1 Past

  • BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 127.07%, which is quite impressive.
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.16% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y137.63%
EPS Next 2Y22.23%
EPS Next 3Y6.7%
EPS Next 5Y9.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2028 2029 2030 2031 2032 2033 200M 400M 600M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

5

4. BDTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 6.03, which indicates a rather cheap valuation of BDTX.
  • Based on the Price/Earnings ratio, BDTX is valued cheaply inside the industry as 97.68% of the companies are valued more expensively.
  • BDTX is valuated cheaply when we compare the Price/Earnings ratio to 25.79, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 6.03
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 99.61% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.78
EV/EBITDA -9.07
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y22.23%
EPS Next 3Y6.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDTX Dividend Analysis

5.1 Amount

  • BDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BDTX Fundamentals: All Metrics, Ratios and Statistics

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (3/18/2026, 8:00:01 PM)

After market: 2.18 +0.01 (+0.46%)

2.17

-0.06 (-2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners77.87%
Inst Owner Change-23.42%
Ins Owners0.62%
Ins Owner Change0.2%
Market Cap123.62M
Revenue(TTM)70.00M
Net Income(TTM)21.48M
Analysts84
Price Target9.31 (329.03%)
Short Float %8.2%
Short Ratio5.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.9%
Min EPS beat(2)24.48%
Max EPS beat(2)37.31%
EPS beat(4)4
Avg EPS beat(4)1123.98%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)572.61%
EPS beat(12)12
Avg EPS beat(12)384.24%
EPS beat(16)16
Avg EPS beat(16)291.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 6.03
Fwd PE N/A
P/S 1.77
P/FCF 5.78
P/OCF 5.78
P/B 0.98
P/tB 0.98
EV/EBITDA -9.07
EPS(TTM)0.36
EY16.59%
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)0.38
FCFY17.31%
OCF(TTM)0.38
OCFY17.31%
SpS1.23
BVpS2.21
TBVpS2.21
PEG (NY)0.04
PEG (5Y)N/A
Graham Number4.24
Profitability
Industry RankSector Rank
ROA 13.62%
ROE 17.03%
ROCE 8.53%
ROIC 6.74%
ROICexc 143.37%
ROICexgc 143.37%
OM 17.33%
PM (TTM) 30.69%
GM N/A
FCFM 30.57%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 171.61%
Profit Quality 99.62%
Current Ratio 8.94
Quick Ratio 8.94
Altman-Z 0.06
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y137.63%
EPS Next 2Y22.23%
EPS Next 3Y6.7%
EPS Next 5Y9.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y114.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year120.25%
EBIT Next 3Y4.07%
EBIT Next 5Y3.64%
FCF growth 1Y128.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.65%
OCF growth 3YN/A
OCF growth 5YN/A

BLACK DIAMOND THERAPEUTICS I / BDTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BLACK DIAMOND THERAPEUTICS I?

ChartMill assigns a fundamental rating of 4 / 10 to BDTX.


What is the valuation status for BDTX stock?

ChartMill assigns a valuation rating of 5 / 10 to BLACK DIAMOND THERAPEUTICS I (BDTX). This can be considered as Fairly Valued.


How profitable is BLACK DIAMOND THERAPEUTICS I (BDTX) stock?

BLACK DIAMOND THERAPEUTICS I (BDTX) has a profitability rating of 4 / 10.


Can you provide the financial health for BDTX stock?

The financial health rating of BLACK DIAMOND THERAPEUTICS I (BDTX) is 7 / 10.